Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
PR Newswire•13/10/2026•08:40 ET
0
Key Highlights
- ➤Lira-cel Phase 1 trial reports no dose-limiting toxicities to date
- ➤Four patients surpassed one year after treatment; one exceeded two years
- ➤Highest-dose patient showed stable disease 90 days after treatment
- ➤Jose Conejo-Garcia will keynote November 3 on ovarian cancer immunotherapy
- ➤Anixa (ANIX) says lira-cel targets FSHR on ovarian cancer cells
Expert Statements
Amit Kumar, Chairman and CEO of Anixa Biosciences
“Dr. Conejo-Garcia's research into the immune biology of ovarian cancer led to the invention of the technology underlying lira-cel, our ovarian cancer CAR-T therapy”
Amit Kumar, Chairman and CEO of Anixa Biosciences
“We are pleased that he will share his insights with the ovarian cancer research community at this conference.”
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference PR Newswire
Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference
Get started
Create a free account to read the full story.